---

The Core Difference: Equivalence vs Conformity

At the highest level, FDA 510(k) and EU MDR ask different questions.

FDA 510(k) asks: Is your device substantially equivalent to an existing legally marketed device?

EU MDR asks: Does your device meet all safety and performance requirements under the regulation?

This difference shapes everything: documentation, timelines, risk, and strategy.

FDA focuses on comparison.
EU MDR focuses on comprehensive proof of compliance.

For digital health, this distinction matters enormously.

---

FDA 510(k): The Predicate-Based Pathway

The 510(k) pathway is the most common route for moderate-risk medical devices in the United States, including many digital health and SaMD products.

To obtain clearance, you must demonstrate that your device is substantially equivalent to a predicate device already on the market.

This means showing similarity in:

• Intended use
• Technological characteristics
• Performance
• Safety profile

For software, this often includes:

• Software documentation (based on FDA software level of concern)
• Software architecture description
• Hazard analysis and risk controls
• Verification and validation testing
• Cybersecurity documentation

The key strategic advantage of 510(k) is leverage: you’re building on an existing regulatory precedent.

If a strong predicate exists, clearance can be relatively efficient.

If no predicate exists, things get more complicated.

---

EU MDR: A System-Based Compliance Model

EU MDR takes a broader and more demanding approach.

Instead of focusing on equivalence to a predicate, EU MDR requires you to demonstrate compliance with the regulation’s General Safety and Performance Requirements (GSPR).

This involves a full technical documentation package, including:

• Device description and specification
• Risk management file (ISO 14971)
• Software lifecycle documentation (IEC 62304)
• Clinical evaluation
• Usability engineering (IEC 62366)
• Post-market surveillance planning
• Quality Management System (ISO 13485)

For many SaMD products, EU MDR classification falls under Class IIa or higher, requiring review by a Notified Body.

Unlike FDA 510(k), there is no shortcut based purely on equivalence.

Even if similar devices exist, you must fully demonstrate compliance.

---

Software Classification: EU MDR Is Often Stricter

One of the biggest surprises for digital health companies is how aggressively EU MDR classifies software.

Under MDR Rule 11, software intended to provide information for diagnostic or therapeutic decisions is often classified as:

• Class IIa
• Class IIb
• or even Class III in some cases

This is frequently higher than expected—and higher than equivalent FDA classification.

Higher classification means:

• More documentation
• Notified Body involvement
• Longer review timelines

This catches many startups off guard.

---

Timelines: FDA Is Often Faster (If You Have a Predicate)

Typical timelines vary, but in practice:

FDA 510(k)
Preparation: 3–6 months
Review: 3–6 months
Total: ~6–12 months

EU MDR CE Marking
Preparation: 6–12 months
Notified Body review: 6–18 months
Total: ~12–24 months

Notified Body capacity remains a major bottleneck under MDR.

For many companies, FDA clearance is the faster initial market entry.

---

Documentation Burden: EU MDR Is Heavier

Both pathways require strong documentation, but EU MDR is more comprehensive.

FDA focuses primarily on demonstrating equivalence and safety.

EU MDR requires a full lifecycle regulatory system, including:

• Continuous post-market surveillance
• Clinical evaluation updates
• Periodic safety reporting
• Ongoing QMS maintenance

EU MDR assumes continuous regulatory oversight, not just premarket clearance.

---

Quality Management System: Required for EU MDR, Expected for FDA

ISO 13485 certification is effectively mandatory for EU MDR.

For FDA, a formal ISO 13485 certificate is not required for 510(k), but FDA Quality System Regulation (21 CFR Part 820) still applies.

In practice, most serious SaMD companies implement ISO 13485 early to support both markets.

It simplifies global expansion and reduces regulatory friction.

---

Strategic Reality: Most Companies Start with FDA

Many digital health companies pursue FDA clearance first.

Reasons include:

• Faster pathway when predicates exist
• More predictable review timelines
• No Notified Body capacity constraints
• Strong commercial credibility

EU MDR is often pursued in parallel or after FDA clearance.

However, this depends heavily on your market strategy and device classification.

---

The Most Common Mistake: Treating Them as the Same

FDA 510(k) and EU MDR are not interchangeable.

A submission prepared only for FDA will almost always be insufficient for EU MDR.

Similarly, EU MDR documentation alone does not guarantee FDA clearance.

Successful companies design their regulatory strategy early to support both pathways efficiently.

This means aligning:

• Software lifecycle documentation
• Risk management structure
• Clinical evidence planning
• Quality Management System implementation

Retrofitting compliance later is far more difficult.

---

Final Thought

FDA 510(k) and EU MDR reflect two different regulatory philosophies.

FDA asks:
Is this device equivalent to something already trusted?

EU MDR asks:
Can you prove this device is safe, effective, and controlled across its entire lifecycle?

Both pathways are achievable but only with the right preparation.

Understanding these differences early is one of the most valuable investments a digital health team can make.

For both submissions, you can save time by using pre-made template documents with guidance. Please refer to 510kinabox for FDA 510(k) submissions and EUMDRinabox for EU MDR submissions.